• AlphaLiquid® Detect is an industry-first personalized, hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients. The assay incorporates a customized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets.
• By delivering exceptional detection across a wide range of targets, AlphaLiquid® Detect enables early detection of recurrence with a significant lead time over radiological imaging.

Patients who are newly diagnosed with stage I-III solid tumor cancer.

Ref : Br J Cancer. 2023 Jun 6. doi: 10.1038/s41416-023-02300-3.

• MRD detection in Colorectal Cancer
• Based on the large cohort multi-center study, MRD positivity as determined by the AlphaLiquid® Detect assay showed a strong association with poor recurrence free survival.